gland pharma glp-1 manufacturing Projects Growth Through Capacity Expansion and Product Diversification Gland Pharma Q4 net profit

PlexusDx integrates provider credentialing (similar to FuturHealth Reviews) with optional genetic testing, helping patients and practitioners understand biological predispositions to medication efficacy and side-effect risk

The growing prevalence of metabolic disease, CKD, and ASCVD have prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks, particularly within the framework of Cardiovascular-Kidney-Metabolic (CKM) Syndrome, irrespective of diabetic status

Inflammation modulation represents another key mechanism

doi: 10.1083/jcb.202112107

Mounjaro contains the same active ingredient as Zepbound (tirzepatide) but is FDA-approved for Type 2 diabetes rather than weight loss